摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

双羟麻黄碱 | 10329-60-9

中文名称
双羟麻黄碱
中文别名
二羟非君
英文名称
(+/-)-erythro-α-methylepinephrine
英文别名
Epinephrin;α-Methyl-adrenalin;3,4-Dihydroxyphenyl-methylaminopropanol;(+/-)-1-(3,4-Dihydroxyphenyl)-2-methylamino-1-propanol;(α-Methylamino-aethyl)-(3.4-dioxy-phenyl)-carbinol;(α-methylamino-ethyl)-(3.4-dioxy-phenyl)-carbinol;3.4-Dihydroxyephedrin;Dioxifedrine;4-[1-hydroxy-2-(methylamino)propyl]benzene-1,2-diol
双羟麻黄碱化学式
CAS
10329-60-9
化学式
C10H15NO3
mdl
MFCD00867056
分子量
197.234
InChiKey
DDBFLXGTCAVAFD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    165-170 °C(Press: 2 Torr)
  • 密度:
    1.236±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    72.7
  • 氢给体数:
    4
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2922509090

反应信息

  • 作为反应物:
    描述:
    双羟麻黄碱 生成 (1RS:2SR)-2-methylamino-1-(3.4-dihydroxy-phenyl)-propanol-(1)
    参考文献:
    名称:
    (.alpha.S)-erythro-.alpha.-Methylepinephrine: preparation and stereoselective binding to adrenergic receptors in rat forebrain
    摘要:
    The enantiomers of a number of catecholamines, including (alpha S)- and (alpha R)-erythro-alpha-methylepinephrine, were evaluated for their capacity to compete for binding sites in rat forebrain homogenates with [3H]prazosin, a ligand which selectively binds to adrenergic receptors of the alpha 1 subtype. (alpha R)-erythro-alpha-Methylepinephrine is devoid of apparent biological activity, but the activity of the alpha S isomer is substantial. The latter is less active than the endogeneous catecholamines, (R)-norepinephrine and (R)-epinephrine, but the stereospecific competition for [3H]prazosin binding sites by the catecholamine isomers with the beta R configuration is additional evidence that (alpha S)-erythro-alpha-methylepinephrine may be a biologically active metabolite of L-alpha-methyl-3,4-dihydroxyphenylalanine.
    DOI:
    10.1021/jm00142a027
点击查看最新优质反应信息

文献信息

  • Somatostatin antagonists and agonists
    申请人:——
    公开号:US20020091090A1
    公开(公告)日:2002-07-11
    Compounds according to the formula A-B-Z-W, wherein A is selected from (C 6 -C 10 )aryl-, or (C 1 -C 9 )heteroaryl-, which groups may be optionally substituted; B is selected from (a) O, NH, NR 10 , —(CH 2 ) k —O—, —(CH 2 ) k —N—, and —(CH 2 ) k —NR 10 —, where R 10 is (C 1 -C 6 )alkyl and where k is 1 to 6 in each case, or 1 where said group (i) through (iv) is optionally substituted by 1 to 4, preferably 1 to 2, groups selected from (C 1 -C 6 )alkyl, halo, and (C 1 -C 6 )alkyl optionally substituted by 1 to 3 halo atoms wherein one of carbon atoms C 1 , C 2 , C 3 and C 4 of said piperidine or piperazine group is optionally replaced by a carbonyl group; Z and W are as herein described; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammels.
    根据公式A-B-Z-W,其中 A选自(C6-C10)芳基或(C1-C9)杂环芳基,这些基团可以选择性地被取代; B选自 (a) O、NH、NR10、—(CH2)k—O—、—( )k—N—和—( )k—NR10—,其中R10为(C1-C6)烷基,k在每种情况下为1至6,或 1所述的该组(i)至(iv)可以选择性地被1至4个,优选1至2个,选自(C1-C6)烷基、卤素和(C1-C6)烷基,该烷基可以选择性地被1至3个卤原子取代,其中所述哌啶哌嗪基团的碳原子C1、C2、C3和C4中的一个可以选择性地被羰基取代; Z和W如本文所述;以及其药学上可接受的盐、溶剂化合物或合物;其制药组合物;以及用于促进哺乳动物分泌生长激素(GH)的方法。
  • NOVEL BRONCHODILATING DIAZAHETEROARYLS
    申请人:Johansson Martin
    公开号:US20120040942A1
    公开(公告)日:2012-02-16
    The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
    这项发明涉及具有通式(I)的新化合物,这些化合物可用于治疗由支气管痉挛引起的疾病或疾病,例如慢性阻塞性肺疾病(COPD)和哮喘。
  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述溶性载体连接的前药的药物组合物和治疗方法。
  • [EN] NOVEL BRONCHODILATING DIAZAHETEROARYLS<br/>[FR] NOUVEAUX DIAZAHÉTÉROARYLES BRONCHODILATATEURS
    申请人:RESPIRATORIUS AB
    公开号:WO2010097410A1
    公开(公告)日:2010-09-02
    The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
    这项发明涉及具有通式(I)的新化合物,这些化合物可用于治疗由支气管痉挛引起的疾病或疾病,例如慢性阻塞性肺疾病(COPD)和哮喘。
  • METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS
    申请人:XENOPORT, INC.
    公开号:US20140243544A1
    公开(公告)日:2014-08-28
    Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.
    提供了制备胺类药物的氨基甲酸酯前药的方法。还提供了在合成氨基甲酸酯前药中有用的碳酸盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫